adamis

FDA Approves Adamis Pharmaceuticals' EpiPen Competitor

FDA Approves Adamis Pharmaceuticals' EpiPen Competitor

Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) shares jumped more than 60% on Thursday, after the U.S Food and Drug Administration (FDA) approved the Adamis’ Epinephrine injection, a generic version of a Mylan N.V.’s EpiPen, which is a..